PPAT
Amidophosphoribosyltransferase
As of the edition of 20 October 2026, PPAT (amidophosphoribosyltransferase, UniProt Q06203) has 2 drugs tested at it and 7 companies on the list, 0 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q06203
- How well studied
- Drug target: an approved drug acts on it
- Solved structures
- 3
- Disease areas
- Immune system; Blood and lymph; Cancer; Digestive system; Skin and connective tissue; Infections; Nervous system; Heart and blood vessels
- Registered trials of its drugs
- 275
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Mercaptopurine anhydrous | Marketed | Phase 4 | none listed |
| Azathioprine | Marketed | Phase 4 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 2 |
| Engaged | 3 |
| Undetermined | 2 |
| Total on the list | 7 |
| Company | Route |
|---|---|
| Lipomed | Route B |
| Mitsubishi Tanabe Pharma | Route B |
The other 5 companies at PPAT
In the product7 companies in all; 5 are not named here, and no score is.
See the 7 companies at PPAT, ranked, with the facts behind eachRequest access. Nothing is shown until you do.